Iressa Advisory Committee Will Not Vote On Oncologic’s Status – AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will not make a regulatory decision on Iressa until survival study data have been fully analyzed, AstraZeneca says; the company expects to complete its data analysis by July. AstraZeneca will present “top-line” data from the ISEL survival study at the March 4 Oncologic Drugs Advisory Committee meeting.
You may also be interested in...
AstraZeneca Seeks Cmte. Input On Further Iressa Marketing Steps
AstraZeneca publishing "Dear Doctor" letter on failed survival study results in oncology journals for foreseeable future. Efforts to inform physicians of trial results have led to a "substantial reduction" in new prescriptions for gefitinib, company says.
AstraZeneca Seeks Cmte. Input On Further Iressa Marketing Steps
AstraZeneca publishing "Dear Doctor" letter on failed survival study results in oncology journals for foreseeable future. Efforts to inform physicians of trial results have led to a "substantial reduction" in new prescriptions for gefitinib, company says.
Tarceva New Rx Share Doubles Since Release Of Failed Iressa Survival Study
New prescription share for Genentech/OSI’s oncologic jumps from about 40% to above 80% following news that AstraZeneca’s Iressa failed to demonstrate a survival benefit. Tarceva sales growth will depend on the ability to differentiate the drug’s profile from that of Iressa, OSI exec says.